Search research articles
Contact Us
Filters
Showing results (71-80 of 93) with videos related to
Page
of 10
Sort By:
Antiviral Therapy
|
April 28, 2017
Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial
Amanda H Yao, Cecilia L Moore, Poh Lian Lim, et al.
Frontiers in Immunology
|
November 9, 2016
CD4<sup>+</sup> T Follicular Helper and IgA<sup>+</sup> B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals
John Zaunders, Mark Danta, Michelle Bailey, et al.
BMC Medicine
|
August 5, 2017
The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study
Swe Swe Thit, Ne Myo Aung, Zaw Win Htet, et al.
The Journal of Infectious Diseases
|
August 10, 2006
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz
Mark A Boyd, Andrew Carr, Kiat Ruxrungtham, et al.
Current Opinion in HIV and AIDS
|
February 20, 2016
Which HIV patients should be screened for osteoporosis: an international perspective
Elena Alvarez, Waldo H Belloso, Mark A Boyd, et al.
The Journal of Infectious Diseases
|
September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial
Helen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
Ebiomedicine
|
August 20, 2015
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis
Nathan W Cummins, Jacqueline Neuhaus, Haitao Chu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 23, 2017
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis
Alexander J Stockdale, Matthew J Saunders, Mark A Boyd, et al.
AIDS Research and Human Retroviruses
|
June 28, 2016
Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study
Edward P Lam, Cecilia L Moore, Eduardo Gotuzzo, et al.
Antiviral Therapy
|
April 28, 2006
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)
Mark A Boyd, Preeyaporn Srasuebkul, Mana Khongphattanayothin, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 93) with videos related to
Sort By:
Page
of 10
Antiviral Therapy
|
April 28, 2017
Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial
Amanda H Yao, Cecilia L Moore, Poh Lian Lim, et al.
Frontiers in Immunology
|
November 9, 2016
CD4<sup>+</sup> T Follicular Helper and IgA<sup>+</sup> B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals
John Zaunders, Mark Danta, Michelle Bailey, et al.
BMC Medicine
|
August 5, 2017
The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study
Swe Swe Thit, Ne Myo Aung, Zaw Win Htet, et al.
The Journal of Infectious Diseases
|
August 10, 2006
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz
Mark A Boyd, Andrew Carr, Kiat Ruxrungtham, et al.
Current Opinion in HIV and AIDS
|
February 20, 2016
Which HIV patients should be screened for osteoporosis: an international perspective
Elena Alvarez, Waldo H Belloso, Mark A Boyd, et al.
The Journal of Infectious Diseases
|
September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial
Helen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
Ebiomedicine
|
August 20, 2015
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis
Nathan W Cummins, Jacqueline Neuhaus, Haitao Chu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 23, 2017
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis
Alexander J Stockdale, Matthew J Saunders, Mark A Boyd, et al.
AIDS Research and Human Retroviruses
|
June 28, 2016
Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study
Edward P Lam, Cecilia L Moore, Eduardo Gotuzzo, et al.
Antiviral Therapy
|
April 28, 2006
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)
Mark A Boyd, Preeyaporn Srasuebkul, Mana Khongphattanayothin, et al.
Page
of 10